TATA-box binding protein associated factor, RNA polymerase I subunit BGenealiases: MGC:9349 · RAF1B · RAFI63 · SL1 · TAFI63
Q-omics provides the consensus-scored TAF1B profile across patient tissues and cancer cell-line models. TAF1B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TAF1B is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TAF1B RNA expression shows 20,633 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where TAF1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF1B survival associations across molecular data types. TAF1B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF1B RNA expression–survival associations across cancer types. High TAF1B expression shows unfavorable associations in LIHC, ACC and LGG, but favorable associations in KIRC, COAD and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TAF1B RNA expression.
This table summarizes TAF1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TAF1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF1B shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, LIHC, COAD and STAD. The HNSC box plot shows higher TAF1B RNA expression in tumor versus normal tissue (log2 FC = +0.755, t-test p < 0.001).
This table shows molecular features associated with TAF1B in patient tissues and cancer cell lines. In patient samples, TAF1B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
